Key facts
- JRNYS’s last known valuation is $109.6M (Aug 2020).
- It has raised $43.5M; the latest was PE Growth/Expansion ($8.6M) in Dec 2024.
- Notable investors include Capital Factory, MicroVentures, Afterburner Capital, Fourward Ventures, QuidelOrtho.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for JRNYS
- ·The full record, as it builds
Funding rounds
No funding rounds for JRNYS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About JRNYS
Developer of a healthcare platform intended to provide symptom-specific telemedicine treatment. The company's platform offers remote patient monitoring, personal health data tracking, and contact tracing while integrating diagnostic tests and triage patients, enabling patients to use their smartphones to initiate medical visits for triage, testing, diagnosis, and treatment anytime.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2016
- Employees
- 57
- Website
- jrnys.com/
- Ownership
- Privately Held (backing)
JRNYS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in JRNYS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on JRNYS in its N-PORT filings yet. We sweep new filings monthly.